Open AccessCerebral Venous Sinus Thrombosis and Covid-19: an Integrative Review
Author(s) -
Maria Theresa de Alencar Ramsdorf,
Camilla Haddad Oliveira,
Gabriela Mayumi Uehara,
Inaê de Oliveira Aquino,
Kamilla Menezes e Souza,
Tayná Boldoni Redígulo,
Anselmo Costa
Publication year - 2021
Language(s) - English
Resource type - Conference proceedings
DOI - 10.5327/1516-3180.519
Subject(s) - medicine , venous thrombosis , thrombosis , cerebral venous sinus thrombosis , asymptomatic , superior sagittal sinus , covid-19 , disease , infectious disease (medical specialty)
Background: Although the majority of those infected by COVID-19 develop an asymptomatic or mild condition, there are those who evolve to a critical condition, such as Cerebral Venous Thrombosis (CVT), which deserves attention, as it is a neurovascular emergency. Objectives: The objective of the abstract is to analyze CVT as a complication of COVID-19. Design and setting: This is an integrative literature review, conducted in the Pubmed database. Methods: The descriptor “cerebral venous thrombosis covid” was used. The inclusion criteria were English studies published in 2020. The exclusion criteria were the non- relevance of the information to the theme. In all, 7 articles were selected. Results: It was observed that most patients were middle-aged men diagnosed with CVT after 7 days of Covid-19 discharge. CVT may be associated with endotheliitis caused by the virus interaction with the Angiotensin Converting Enzyme receptor, also with an abnormal proliferation of cytokines, and both of them favor vasoconstriction and hypercoagulopathy. It has been proposed that the disease may induce a prothrombotic state by the elevated levels of circulating fibrinogen, D-dimer, and pro-thrombotic microparticles. Furthermore, increasing levels of antiphospholipid antibodies detected in patients with COVID-19, such as anti-cardiolopin IgA, anti-β2-glycoprotein I IgA and IgG may precipitate hypercoagulability and vascular infarctions. Conclusion: This review shows the influence of the post-COVID on the occurrence of TVC. However, the studies are still incipient and have not systematically described other previous prothrombotic conditions that may be additive factors.